Qilu Pharmaceutical Co., Ltd., commonly known as Qilu Pharma, is a prominent player in the global pharmaceutical industry, headquartered in Jinan, Shandong Province, China. Founded in 1992, the company has established a strong presence in various operational regions, including Asia, Europe, and North America. Specialising in the research, development, and manufacturing of innovative medicines, Qilu Pharma focuses on areas such as oncology, cardiovascular diseases, and central nervous system disorders. Its commitment to quality and innovation has led to the successful launch of several core products, including generic and proprietary drugs that stand out for their efficacy and safety. With a robust market position, Qilu Pharmaceutical has achieved notable milestones, including numerous international certifications and partnerships, solidifying its reputation as a trusted provider in the pharmaceutical landscape.
How does Qilu Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Qilu Pharmaceutical's score of 15 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Qilu Pharmaceutical, headquartered in China (CN), currently does not have publicly available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This lack of data suggests that Qilu Pharmaceutical may still be in the early stages of formalising its climate commitments or reporting on its carbon footprint. In the pharmaceutical industry, companies are increasingly recognising the importance of addressing climate change and reducing greenhouse gas emissions across all scopes—Scope 1 (direct emissions), Scope 2 (indirect emissions from energy), and Scope 3 (indirect emissions from the value chain). As the industry evolves, stakeholders expect firms like Qilu Pharmaceutical to establish clear targets and strategies to mitigate their environmental impact. Without specific emissions data or reduction initiatives, it remains unclear how Qilu Pharmaceutical plans to align with global climate goals or contribute to sustainability efforts within the sector.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Qilu Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.